Sun Pharma Q2 Results: Net profit grows 28% YoY to ₹3,040 crore; formulation sales in the US up 20%

Total revenue from operations came in at ₹13,291.39 crore, up 9% from ₹12,192.41 crore registered in the year-ago period. 

Basic earnings per share (EPS) for the September 2024 quarter stood at ₹12.7 against ₹9.9 in the year-ago period. 

The pharma major said its EBITDA came in ₹3,939 crore (including other operating revenues), up 23.9% YoY, with a resulting EBITDA margin of 29.6%. 

Dilip Shanghvi, Chairman and Managing Director of the Company, said, “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late-stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.”

India Formulations

US Formulations

Formulation sales in the US were US$ 517 million for Q2 FY25, growing by 20.3% over Q2 last year and accounting for approximately 33% of total consolidated sales. For the first half, sales were US$ 983 million, growing by 9.1% over the same period last year.

Emerging Markets (EM) Formulations

Formulation sales in emerging markets were US$ 293 million for Q2 FY25, growing by 3.2% over Q2 last year and accounting for approximately 18% of total consolidated sales. For the first half, sales were US$ 577 million, growing by 5.9% over the same period last year.

Rest of World (ROW) Formulations

Formulation sales in the Rest of World (ROW) markets, excluding India, the US, and emerging markets, were US$199 million in Q2 FY25, declining by 3.5% vs. Q2 last year and accounting for approximately 13% of total consolidated sales. For the first half, sales were US$ 388 million, declining by 3.2% over the same period last year.

R&D Update

Consolidated R&D investment was ₹792.9 crore for Q2 FY25, or 6% of sales, as compared to ₹773.4 crore for Q2 last year. For the first half, R&D expense was ₹1,586.9 crore, or 6.2% of sales. 

Active Pharmaceutical Ingredients (API)

External sales of API were ₹533.8 crore in Q2 FY25, growing by 7.4% over Q2 last year. For the first half, API sales were at ₹1028.4 crore, declining slightly over the first half of last year.

"Our API business imparts the benefits of vertical integration and continuity of supply chain for our formulations business. We continue to focus on increasing API supply for captive consumption of key products," the company said in its earnings release.